Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | F13A1 | P00488 | 1/20 | 0.51 |
| ▸ | ESRRG | P62508 | 3/20 | 0.46 |
| ▸ | ESRRB | O95718 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.42 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.42 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.42 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6433557 | 0.91 | KDM4E (0.61) | KDM4EF13A1ESRRGESRRBSMN1; SMN2 | |
| SCHEMBL4463389 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2GAAALDH1A1TAAR1 | |
| SCHEMBL8699335 | 0.81 | POLB (0.55) | KDM4EF13A1ESRRGSMN1; SMN2PLAAT3 | |
| SCHEMBL23346356 | 0.78 | TRPV1 (0.50) | KDM4EF13A1ESRRGESRRBSMN1; SMN2 | |
| SCHEMBL5540114 | 0.78 | KDM4E (0.66) | KDM4EF13A1ESRRGESRRBSMN1; SMN2 | |
| SCHEMBL4179064 | 0.78 | HPGD (0.57) | SMN1; SMN2NPC1RAB9APLAAT3PLAAT5 | |
| SCHEMBL7332995 | 0.77 | CA1 (0.41) | KDM4EF13A1SMN1; SMN2GAAPLAAT3 | |
| SCHEMBL5553483 | 0.76 | PLAAT3 (0.58) | SMN1; SMN2PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL4700346 | 0.76 | ESRRG (0.54) | KDM4EF13A1ESRRGSMN1; SMN2GFER | |
| SCHEMBL4702861 | 0.76 | ALDH1A1 (0.47) | KDM4EF13A1SMN1; SMN2PLAAT3PLAAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| EP-1546086-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004002939-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | WO | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | KDM4E 2289/4885F13A1 2186/4885ESRRG 814/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | KDM4E 1554/4885F13A1 851/4885ESRRG 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.